OS Therapies - Health Technology Insights

April 9, 2025
HealthTech Media Room
HealthTech News, Pharmaceuticals

OS Therapies Acquires Advaxis Immunotherapies Assets from Ayala

Company now listeria-based cancer immunotherapy world leader OS Therapies , a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it has completed the acquisition of...

January 30, 2025
HealthTech Media Room
General Healthcare Services, Health, Health Services, HealthTech News

OS Therapies Agrees to Acquire All Listeria Monotygenes-based

OS Therapies, a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based...

January 3, 2025
HealthTech Media Room
General Healthcare Services, Health, HealthTech News

OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online

OS Therapies, a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, has partnered with B2i Digital to enhance investor outreach. B2i Digital will implement data-driven strategies to...

OS Therapies Acquires Advaxis Immunotherapies Assets from Ayala

OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online

Fuel up with free Health Tech Insights

Quick Links

Insights

Get in touch

Follow Us

Our Other Brands